GSTM1 and gastrointestinal stromal tumor: Furthermore, the 62005 intergroup phase III trial from EORTC-STBSG [12] in advanced/metastatic GIST patients reported that Hb level is significantly correlated to imatinib response and to progression free survival (PFS) with high imatinib response and favourable PFS predicted by high Hb level.